H3B-8800–treated SF3B1K700E group showed the lowest bone marrow and spleen infiltration after H3B-8800 treatment, arguing that H3B-8800 displays preferential lethality towards infiltrating SF3B1-mutant CLL cells. The gene discussed is SF3B1; the disease is B-cell chronic lymphocytic leukemia.